MOODY’S-ESG-SOLUTIONS
Moody’s today launched Moody’s ESG360™, an easy-to-use platform that provides portfolio managers with ESG analyst-verified scores and modelled ESG and climate intelligence on private and public companies to bring clarity and confidence to investment decisions on environmental, social and governance (ESG) issues.
“To understand the short- and long-term impact of ESG and climate exposures, market participants need a holistic and reliable view of risks and opportunities,” said Andrea Blackman, Managing Director – Global Head of Moody’s ESG Solutions. “The launch of Moody’s ESG360™ demonstrates our commitment to providing comprehensive coverage to help portfolio managers make sustainable decisions with confidence. Coverage is much more than just a number; it’s a commitment to providing granular and clearly defined data, scores, and assessments – all delivered through platforms that meet customer needs.”
Moody’s ESG360™ allows portfolio managers to identify ESG leaders and laggards across themes, sectors, and regions, monitor and report on portfolio level performance across a broad range of research lines, and analyze key risk metrics at both the portfolio and entity level. All data points will be clearly labeled with their relevance to industry standards and traceable to their source.
At launch, Moody’s ESG360™ provides access to Moody’s physical and transition climate risk data sets across a recently expanded universe of 10,000 companies globally. In the coming months, the platform will be further enhanced with Moody’s ESG insights, including coverage of 300 million public and private companies through a combination of modelled and ESG analyst-verified scores.
Driven by a double materiality approach that accounts for both financial and stakeholder impacts, Moody’s ESG data, scores, and assessments provide a comprehensive view of the ESG performance of companies – including small and medium-sized enterprises (SMEs). This enables a unique assessment of how companies can create sustainable value for the environment, society, and stakeholders, as well as how companies are positioned to manage their exposure and response to ESG risks and opportunities.
Alongside Moody’s ESG360™, Moody’s recently launched a corporate engagement platform, Moody’s ESG360™ Connect, which enables corporates to easily connect with Moody’s regarding their sustainability disclosures and ensure accurate representation of their ESG data, ultimately expanding the data coverage that feeds into Moody’s ESG solutions.
To learn more about Moody’s ESG360™ or get a demo, visit: http://www.moodys.com/moodys-esg360 .
Sustainability is at the core of Moody's business, building better business, better lives and better solutions to create long-term value for society, the environment and the economy. For more information on Moody’s sustainability commitments, visit: https://about.moodys.io/sustainability
ABOUT MOODY’S ESG SOLUTIONS
Moody’s ESG Solutions is a business unit of Moody’s Corporation serving the growing global demand for ESG and climate insights. The group leverages data and expertise across ESG, climate risk, and sustainable finance, and aligns with Moody's Investors Service and Moody's Analytics to deliver a comprehensive, integrated suite of ESG and climate risk solutions including ESG scores, analytics, Sustainability Ratings and Sustainable Finance Reviewer/certifier services.
For more information visit, Moody’s ESG hub at www.moodys.com/esg .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220426005612/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Aesyra Demonstrates Significant Sleep Bruxism Reduction in Clinical Study26.1.2026 09:00:00 CET | Press release
Aesyra SA, a Swiss medtech company developing innovative digital therapeutics for dental and sleep-related disorders, today announced the successful completion of its clinical investigation evaluating the efficacy and safety of AesyBite™ Active, an intelligent oral appliance designed to treat and prevent sleep bruxism through biofeedback. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260126533019/en/ AesyBite Custom smart nightguard by Aesyra SA. The clinical investigation demonstrated that AesyBite™ Active achieved a statistically significant and clinically meaningful reduction in sleep bruxism activity, exceeding the predefined performance target. Strong and robust clinical outcomes In the study (Identifier: NCT06153810), involving 26 adult patients with confirmed sleep bruxism, activation of the AesyBite Active biofeedback system resulted in a 60.6% reduction in total sleep bruxism duration per hour compared to baseline
Franklin Templeton Aligns Alternative Credit Firms Under BSP Brand26.1.2026 08:58:00 CET | Press release
Benefit Street Partners and Alcentra align under a single, refreshed BSP brand.Move reflects client demand for a specialist, integrated and global credit platform.Franklin Templeton’s alternative credit platform on track to exceed $100bn in 2026.BSP outlines further growth plans including expansion in the Middle East and Asia.New research says 51% of institutional investors will increase credit allocation in 2026.81% of institutions say a specialist focus on credit is the top attribute for performance. Franklin Templeton’s US and European alternative credit businesses, Benefit Street Partners and Alcentra, have now aligned under an updated Benefit Street Partners (BSP) brand. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260123270080/en/ David Manlowe, CEO of Benefit Street Partners The move is the final step in BSP and Alcentra’s integration – two pioneering alternative credit firms that Franklin Templeton acquired in 2019
Samsung Epis Holdings Reports Fourth Quarter and Fiscal Year 2025 Financial Results26.1.2026 08:00:00 CET | Press release
In its first financial results announcement after the spin-off, Samsung Bioepis recorded FY2025 revenue of KRW 1.672 trillion, highest annual revenue in its 14-year historyExcluding milestone revenue, annual sales revenue grew 28% year-over-year (YoY), recording KRW 1.626 trillion, with 101% YoY growth in operating profit to KRW 330.8 billion Samsung Epis Holdings (KRX: 0126Z0), an investment company dedicated to innovations in biopharmaceuticals and biotechnology, today announced financial results for the fourth quarter and fiscal year 2025. “We are very pleased to report strong year-to-date sales growth in our first financial results following the spin-off. Our organic growth has been driven by solid performance across our biosimilars portfolio," said Kyung-Ah Kim, President and Chief Executive Officer (CEO) of Samsung Epis Holdings. “We are continuing to make meaningful progress in our regulatory and commercial milestones with our existing biosimilars portfolio, while strategically
Syngenta and Statkraft Sign Five-Year Virtual Power Purchase Agreement26.1.2026 08:00:00 CET | Press release
Virtual wind PPA with guarantees of origin to decarbonize Syngenta's plants in Europe Important element in carbon reduction journey for Syngenta AG Syngenta, one of the world’s biggest agricultural innovation companies, and Statkraft, a leading provider of innovative green energy solutions in Europe, have signed a virtual power purchase agreement (vPPA) covering Syngenta’s CP & Seeds operations for a period of five years. The volume amounts to 125 GWh per year and a total of 625 GWh of green electricity by the end of the contract in 2030. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260125701845/en/ Syngenta and Statkraft sign five-year virtual power purchase agreement With the vPPA, Statkraft is supporting Syngenta in advancing its sustainability strategy through the purchase of renewable energy. "This is Syngenta's first vPPA, marking a pivotal step in our decarbonization strategy," said Rachel Stenson Bugnon, Global Hea
Merz Therapeutics Submits Application to the European Medicines Agency for New Indication of XEOMIN® in Pediatric Spasticity26.1.2026 08:00:00 CET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that it has completed the regulatory submission for XEOMIN® (incobotulinumtoxinA) for the treatment of spasticity of the lower and upper limb in children and adolescents aged 2–17 years in the European Union (EU) and European Economic Area (EEA). If approved, the indication would expand access to an established botulinum neurotoxin therapy for some of the youngest and most vulnerable patients across Europe. Spasticity is a common and often debilitating condition in children and adolescents with certain neurological conditions, leading to increased muscle tone that can significantly limit movement, function and independence. One of the most common underlying causes of spasticity in children is cerebral palsy (CP), the most frequent motor disability in childhood, with spastic forms accounting for approximately 80% of all cases. In more severe cases, spasticity associated with CP can also affect spe
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
